GlassScriptPhysician profile
Clare Daniel Doss
NPI 1437804085
$4,537.07
in general payments reported to CMS, 2019-2025
36 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,964 · 2023: $1,778 · 2024: $369 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,403.88 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $567.76 | 2022-2025 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $476.43 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $440.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $419.26 | 2022-2025 | |
| Glaxosmithkline, LLC. | $353.35 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $299.09 | 2022-2024 | |
| Astellas Pharma US INC | $274.75 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $264.60 | 2022-2025 | Evenity, Otezla, Repatha |
| Esperion Therapeutics, INC. | $198.32 | 2022-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.34 | 2022-2023 | Spiriva |
| Merck Sharp & Dohme LLC | $131.81 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $106.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.22 | 2022 | |
| Insulet Corporation | $66.95 | 2023 | Omnipod |
| Pfizer INC. | $61.08 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $57.72 | 2023 | Korlym |
| Impel Pharmaceuticals INC. | $53.77 | 2022-2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $48.95 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $47.73 | 2023 | |
| Axsome Therapeutics, INC. | $44.25 | 2023-2025 | Auvelity |
| Ironwood Pharmaceuticals, INC | $41.26 | 2022-2023 | Linzess |
| Sumitomo Pharma America, INC. | $40.64 | 2023 | Gemtesa |
| Abbott Laboratories | $31.98 | 2022-2023 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $27.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.29 | 2022-2023 | Trintellix |
| Lifescan, INC. | $21.29 | 2022 | |
| Corium, LLC | $20.95 | 2023 | Adlarity |
| Philips North America LLC | $20.44 | 2022 | |
| Forte Bio-Pharma LLC | $19.62 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.60 | 2025 | Rexulti |
| Dexcom, INC. | $17.33 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $17.02 | 2022 | |
| Gilead Sciences, INC. | $16.10 | 2024 | |
| Ardelyx, INC. | $15.53 | 2024 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $15.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.98 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clare Doss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.